Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1975 1
1980 1
1981 1
1984 1
1990 1
1994 2
1995 3
1996 2
1997 4
1998 3
1999 5
2000 3
2001 4
2002 6
2003 4
2004 7
2005 3
2006 7
2007 7
2008 6
2009 8
2010 12
2011 13
2012 16
2013 16
2014 19
2015 14
2016 24
2017 23
2018 28
2019 33
2020 35
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

278 results
Results by year
Filters applied: . Clear all
Page 1
Sickle-cell disease.
Rees DC, Williams TN, Gladwin MT. Rees DC, et al. Lancet. 2010 Dec 11;376(9757):2018-31. doi: 10.1016/S0140-6736(10)61029-X. Epub 2010 Dec 3. Lancet. 2010. PMID: 21131035 Review.
Sickle-cell disease is one of the most common severe monogenic disorders in the world. ...More work is needed to develop effective treatments that specifically target pathophysiological changes and clinical complications of sickle-cell disease....
Sickle-cell disease is one of the most common severe monogenic disorders in the world. ...More work is needed to develop effec
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP. Ataga KI, et al. N Engl J Med. 2017 Feb 2;376(5):429-439. doi: 10.1056/NEJMoa1611770. Epub 2016 Dec 3. N Engl J Med. 2017. PMID: 27959701 Free PMC article. Clinical Trial.
BACKGROUND: The up-regulation of P-selectin in endothelial cells and platelets contributes to the cell-cell interactions that are involved in the pathogenesis of vaso-occlusion and sickle cell-related pain crises. ...The primary end point was the annua …
BACKGROUND: The up-regulation of P-selectin in endothelial cells and platelets contributes to the cell-cell interactions that …
Sickle cell disease: a comprehensive program of care from birth.
de Montalembert M, Tshilolo L, Allali S. de Montalembert M, et al. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):490-495. doi: 10.1182/hematology.2019000053. Hematology Am Soc Hematol Educ Program. 2019. PMID: 31808910 Free PMC article. Review.
As more children are appropriately being diagnosed, the burden of sickle cell disease is increasing greatly in Africa and in high-resource countries such as the United States and Europe. ...Comprehensive programs targeting the prevention of pneumococca …
As more children are appropriately being diagnosed, the burden of sickle cell disease is increasing greatly in Africa and in h …
Pain and sickle cell disease.
Aich A, Jones MK, Gupta K. Aich A, et al. Curr Opin Hematol. 2019 May;26(3):131-138. doi: 10.1097/MOH.0000000000000491. Curr Opin Hematol. 2019. PMID: 30893088 Review.
PURPOSE OF REVIEW: Pain is a major comorbidity of sickle cell disease (SCD). Opioids are the mainstay for pain treatment but remain suboptimal. ...The origin of pain involves neurovascular and neuroimmune interactions from the periphery and/or central nervous system …
PURPOSE OF REVIEW: Pain is a major comorbidity of sickle cell disease (SCD). Opioids are the mainstay for pain treatment but r …
Targeting pain at its source in sickle cell disease.
Gupta K, Jahagirdar O, Gupta K. Gupta K, et al. Am J Physiol Regul Integr Comp Physiol. 2018 Jul 1;315(1):R104-R112. doi: 10.1152/ajpregu.00021.2018. Epub 2018 Mar 28. Am J Physiol Regul Integr Comp Physiol. 2018. PMID: 29590553 Free PMC article. Review.
Sickle cell disease (SCD) is a genetic disorder associated with hemolytic anemia, end-organ damage, reduced survival, and pain. ...Additionally, patients with SCD often develop chronic persistent pain. Currently, sickle cell pain is treated with opioid
Sickle cell disease (SCD) is a genetic disorder associated with hemolytic anemia, end-organ damage, reduced survival, and pain
Challenges in the Management of Sickle Cell Disease During SARS-CoV-2 Pandemic.
Alsayegh F, Mousa SA. Alsayegh F, et al. Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620955240. doi: 10.1177/1076029620955240. Clin Appl Thromb Hemost. 2020. PMID: 32873056 Free PMC article. Review.
The management of sickle cell disease (SCD) and its complications in the COVID-19 era is very challenging. ...Since the outbreak of SARS-CoV-2 pandemic, little data has been published about SCD concerning clinical presentation with COVID-19 and management. Hydrox
The management of sickle cell disease (SCD) and its complications in the COVID-19 era is very challenging. ...Since the outbre …
The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management.
Darbari DS, Sheehan VA, Ballas SK. Darbari DS, et al. Eur J Haematol. 2020 Sep;105(3):237-246. doi: 10.1111/ejh.13430. Epub 2020 May 19. Eur J Haematol. 2020. PMID: 32301178 Review.
The pathophysiology of VOCs includes polymerization of abnormal sickle hemoglobin, inflammation, and adhesion. Hydroxyurea, L-glutamine, crizanlizumab, and voxelotor have been approved by the US Food and Drug Administration for reducing the frequency of VOCs; the Eu …
The pathophysiology of VOCs includes polymerization of abnormal sickle hemoglobin, inflammation, and adhesion. Hydroxyurea, L- …
Review/overview of pain in sickle cell disease.
Ballas SK, Darbari DS. Ballas SK, et al. Complement Ther Med. 2020 Mar;49:102327. doi: 10.1016/j.ctim.2020.102327. Epub 2020 Feb 3. Complement Ther Med. 2020. PMID: 32147066 Review.
Sickle cell disease (SCD) is a highly complex inherited disorder of hemoglobin structure. ...The search for additional pharmacotherapeutic agents that could be used singly or in combination with hydroxyurea and/or l-glutamine awaits their dawn hopefully in th
Sickle cell disease (SCD) is a highly complex inherited disorder of hemoglobin structure. ...The search for additional pharmac
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Wang WC. Estcourt LJ, et al. Cochrane Database Syst Rev. 2017 Jan 17;1(1):CD003146. doi: 10.1002/14651858.CD003146.pub3. Cochrane Database Syst Rev. 2017. PMID: 28094851 Free PMC article. Updated. Review.
Sickle cell disease can cause severe pain, significant end-organ damage, pulmonary complications, and premature death. ...SELECTION CRITERIA: Randomised controlled trials comparing red blood cell transfusions as prophylaxis for stroke in people with sickle
Sickle cell disease can cause severe pain, significant end-organ damage, pulmonary complications, and premature death. ...SELE
American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.
DeBaun MR, Jordan LC, King AA, Schatz J, Vichinsky E, Fox CK, McKinstry RC, Telfer P, Kraut MA, Daraz L, Kirkham FJ, Murad MH. DeBaun MR, et al. Blood Adv. 2020 Apr 28;4(8):1554-1588. doi: 10.1182/bloodadvances.2019001142. Blood Adv. 2020. PMID: 32298430 Free PMC article.
BACKGROUND: Central nervous system (CNS) complications are among the most common, devastating sequelae of sickle cell disease (SCD) occurring throughout the lifespan. OBJECTIVE: These evidence-based guidelines of the American Society of Hematology are intended to su …
BACKGROUND: Central nervous system (CNS) complications are among the most common, devastating sequelae of sickle cell disease …
278 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page